2025 Q3 -tulosraportti
Vain PDF
67 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
221
Myynti
Määrä
10 355
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 99 | - | - | ||
| 7 819 | - | - | ||
| 2 082 | - | - | ||
| 7 461 | - | - |
Ylin
1,625VWAP
Alin
1,55VaihtoMäärä
0,3 198 725
VWAP
Ylin
1,625Alin
1,55VaihtoMäärä
0,3 198 725
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 25.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 27.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·22.1.Imagine that this hits price 10 by 2026
·1 päivä sitten · MuokattuA couple of positive news items are enough, and then everyone will look towards the first milestone from Gilead 10-15mUSD low-hanging fruit in Q4. Extremely low risk for a multibagger when the company is valued at cash. The market will wake up. 5-10x from here in 12-18 months fully reasonable if everything goes according to plan.
·17.12.2025My tip is buy and hold. Try to be a bit long-term, it will pay off. When news comes, it shoots up immediately, then it's tough to be on the sidelines. It would take a lot for there not to be positive news. I find it hard to believe that Gilead went in on a chance.- ·16.12.2025I honestly believe Sprint Bioscience can hit a share price of +10 in 2026, and it's not because I'm expecting a miracle. It's because they have a fairly simple model: they find promising "targets" against diseases early and make agreements with larger companies that have the money to run the expensive trials. And the important thing is that they have already proven they can get big players to sign – including a deal with Gilead, where money came in immediately, and much more can come later if things develop as they should. When a small biotech company is first seen as someone who can repeat these kinds of agreements (and not just hope for a single jackpot), the market can suddenly price them completely differently. And that's why I'm looking towards 2026: typically, just 1-2 strong news items, for example, another partnership agreement or clear data on one of their projects, are needed before the entire case can be "re-rated" and the share price rises sharply. Of course, there is risk in biotech, but if they continue to deliver and land deals, then I think a price of 10 or higher is a realistic goal, not just hype.·16.12.2025 · MuokattuI'm on the same page and have followed the company for many years. The situation now is better than ever. If there's ever a time, it's "now now it's happening". TREX1 has been sold for a historically high upfront, 14mUSD+400mUSD in potential milestones. To begin with, the company has a runway for 2-3 years, so financial risk in the coming years is not on the cards with 15mUSD in cash and a low burn rate. If you calculate it quickly, the stock should be twice as high if you combine the market cap before and after the deal, but this will probably correct itself when more people find their way in. There are certainly sellers who are happy with a quick profit and move on, but soon the shares will run out, and then the market and the new owners will look ahead to 2026. I estimate 1-2 deals in 2026. STK25 can be sold already in Q1 as it has been under evaluation by a customer in Singapore since June 2025. The CEO has talked about platform agreements in presentations since H1, and said that it is something they expect to deliver shortly. This would mean recurring revenue and another upfront. Then we also have high interest in DCPS and NNMT, two target proteins that could achieve similar, if not higher, sales value as the deal the company just made with Gilead. The good thing about time is that if Sprint delivers more deals in 2026, the market will start to factor in low-hanging milestones from Gilead that can kick in from Q4 2026. I expect 20-30mUSD that could come in 2026-2027 if TREX1 enters clinical trials and passes Phase I. Then the stock should be at 10 kr just based on that. Safety validations from several institutes indicate that TREX1 is a safe target protein, which increases the probability of a successful Phase I. As long as the TREX1 program progresses under Gilead, this stock is cheap under 3 kr. Sprint succeeding in making deals with Gilead is also a seal of quality that benefits negotiations for other programs. It's proof that they pay for world-class drug discovery.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22.1.Imagine that this hits price 10 by 2026·1 päivä sitten · MuokattuA couple of positive news items are enough, and then everyone will look towards the first milestone from Gilead 10-15mUSD low-hanging fruit in Q4. Extremely low risk for a multibagger when the company is valued at cash. The market will wake up. 5-10x from here in 12-18 months fully reasonable if everything goes according to plan.
- ·17.12.2025My tip is buy and hold. Try to be a bit long-term, it will pay off. When news comes, it shoots up immediately, then it's tough to be on the sidelines. It would take a lot for there not to be positive news. I find it hard to believe that Gilead went in on a chance.
- ·16.12.2025I honestly believe Sprint Bioscience can hit a share price of +10 in 2026, and it's not because I'm expecting a miracle. It's because they have a fairly simple model: they find promising "targets" against diseases early and make agreements with larger companies that have the money to run the expensive trials. And the important thing is that they have already proven they can get big players to sign – including a deal with Gilead, where money came in immediately, and much more can come later if things develop as they should. When a small biotech company is first seen as someone who can repeat these kinds of agreements (and not just hope for a single jackpot), the market can suddenly price them completely differently. And that's why I'm looking towards 2026: typically, just 1-2 strong news items, for example, another partnership agreement or clear data on one of their projects, are needed before the entire case can be "re-rated" and the share price rises sharply. Of course, there is risk in biotech, but if they continue to deliver and land deals, then I think a price of 10 or higher is a realistic goal, not just hype.·16.12.2025 · MuokattuI'm on the same page and have followed the company for many years. The situation now is better than ever. If there's ever a time, it's "now now it's happening". TREX1 has been sold for a historically high upfront, 14mUSD+400mUSD in potential milestones. To begin with, the company has a runway for 2-3 years, so financial risk in the coming years is not on the cards with 15mUSD in cash and a low burn rate. If you calculate it quickly, the stock should be twice as high if you combine the market cap before and after the deal, but this will probably correct itself when more people find their way in. There are certainly sellers who are happy with a quick profit and move on, but soon the shares will run out, and then the market and the new owners will look ahead to 2026. I estimate 1-2 deals in 2026. STK25 can be sold already in Q1 as it has been under evaluation by a customer in Singapore since June 2025. The CEO has talked about platform agreements in presentations since H1, and said that it is something they expect to deliver shortly. This would mean recurring revenue and another upfront. Then we also have high interest in DCPS and NNMT, two target proteins that could achieve similar, if not higher, sales value as the deal the company just made with Gilead. The good thing about time is that if Sprint delivers more deals in 2026, the market will start to factor in low-hanging milestones from Gilead that can kick in from Q4 2026. I expect 20-30mUSD that could come in 2026-2027 if TREX1 enters clinical trials and passes Phase I. Then the stock should be at 10 kr just based on that. Safety validations from several institutes indicate that TREX1 is a safe target protein, which increases the probability of a successful Phase I. As long as the TREX1 program progresses under Gilead, this stock is cheap under 3 kr. Sprint succeeding in making deals with Gilead is also a seal of quality that benefits negotiations for other programs. It's proof that they pay for world-class drug discovery.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
221
Myynti
Määrä
10 355
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 99 | - | - | ||
| 7 819 | - | - | ||
| 2 082 | - | - | ||
| 7 461 | - | - |
Ylin
1,625VWAP
Alin
1,55VaihtoMäärä
0,3 198 725
VWAP
Ylin
1,625Alin
1,55VaihtoMäärä
0,3 198 725
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 25.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 27.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
2025 Q3 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 25.11.2025 | |
| 2025 Q2 -tulosraportti | 27.8.2025 | |
| 2025 Q1 -tulosraportti | 27.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22.1.Imagine that this hits price 10 by 2026·1 päivä sitten · MuokattuA couple of positive news items are enough, and then everyone will look towards the first milestone from Gilead 10-15mUSD low-hanging fruit in Q4. Extremely low risk for a multibagger when the company is valued at cash. The market will wake up. 5-10x from here in 12-18 months fully reasonable if everything goes according to plan.
- ·17.12.2025My tip is buy and hold. Try to be a bit long-term, it will pay off. When news comes, it shoots up immediately, then it's tough to be on the sidelines. It would take a lot for there not to be positive news. I find it hard to believe that Gilead went in on a chance.
- ·16.12.2025I honestly believe Sprint Bioscience can hit a share price of +10 in 2026, and it's not because I'm expecting a miracle. It's because they have a fairly simple model: they find promising "targets" against diseases early and make agreements with larger companies that have the money to run the expensive trials. And the important thing is that they have already proven they can get big players to sign – including a deal with Gilead, where money came in immediately, and much more can come later if things develop as they should. When a small biotech company is first seen as someone who can repeat these kinds of agreements (and not just hope for a single jackpot), the market can suddenly price them completely differently. And that's why I'm looking towards 2026: typically, just 1-2 strong news items, for example, another partnership agreement or clear data on one of their projects, are needed before the entire case can be "re-rated" and the share price rises sharply. Of course, there is risk in biotech, but if they continue to deliver and land deals, then I think a price of 10 or higher is a realistic goal, not just hype.·16.12.2025 · MuokattuI'm on the same page and have followed the company for many years. The situation now is better than ever. If there's ever a time, it's "now now it's happening". TREX1 has been sold for a historically high upfront, 14mUSD+400mUSD in potential milestones. To begin with, the company has a runway for 2-3 years, so financial risk in the coming years is not on the cards with 15mUSD in cash and a low burn rate. If you calculate it quickly, the stock should be twice as high if you combine the market cap before and after the deal, but this will probably correct itself when more people find their way in. There are certainly sellers who are happy with a quick profit and move on, but soon the shares will run out, and then the market and the new owners will look ahead to 2026. I estimate 1-2 deals in 2026. STK25 can be sold already in Q1 as it has been under evaluation by a customer in Singapore since June 2025. The CEO has talked about platform agreements in presentations since H1, and said that it is something they expect to deliver shortly. This would mean recurring revenue and another upfront. Then we also have high interest in DCPS and NNMT, two target proteins that could achieve similar, if not higher, sales value as the deal the company just made with Gilead. The good thing about time is that if Sprint delivers more deals in 2026, the market will start to factor in low-hanging milestones from Gilead that can kick in from Q4 2026. I expect 20-30mUSD that could come in 2026-2027 if TREX1 enters clinical trials and passes Phase I. Then the stock should be at 10 kr just based on that. Safety validations from several institutes indicate that TREX1 is a safe target protein, which increases the probability of a successful Phase I. As long as the TREX1 program progresses under Gilead, this stock is cheap under 3 kr. Sprint succeeding in making deals with Gilead is also a seal of quality that benefits negotiations for other programs. It's proof that they pay for world-class drug discovery.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
221
Myynti
Määrä
10 355
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 99 | - | - | ||
| 7 819 | - | - | ||
| 2 082 | - | - | ||
| 7 461 | - | - |
Ylin
1,625VWAP
Alin
1,55VaihtoMäärä
0,3 198 725
VWAP
Ylin
1,625Alin
1,55VaihtoMäärä
0,3 198 725
Välittäjätilasto
Dataa ei löytynyt